In particular, one of them, called 53L10, a tri-specific T-cell engager targeting 5T4 and PD-L1, showed the most promising anti-tumor efficacy in vitro by inducing 80–100% of tumor lysis at very low concentrations. This evidence concerns the gene TPBG and neoplasm.